|  Sign up!  


Return to Course Listing



CME: Oncology Patients at High Risk of Bone Fracture: Advances in Pharmacotherapy


Program Description / Statement of Need:

In this online CME self-learning program:


The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years because statistics have shown it has about a 25% better 10 year mortality outcome when compared to observation alone. It has been associated with reductions in morbidity and metastases and increased survival rates when combined with radiation both in more advanced stages of the disease and in disease confined to the prostate. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients. Studies have shown that about 19.4% of men who received androgen deprivation therapy experienced a fracture, and 5.2% of them required hospitalization.


Patients taking AIs or androgen deprivation therapy have benefited from vitamin D, calcium, and bisphosphonate therapy. Denosumab, used in patients receiving AIs has been shown to significantly increase lumbar spine BMD by 7.6% from baseline versus placebo.Increases were observed as early as 1 month from beginning of therapy and were not influenced by duration of AI therapy.Increases in BMD can also be seen in the hip, total body, and femoral neck.




Faculty introduction, disclosures

Introduction content: cursory refresher and review of oncology patients at high risk of bone fracture [Learning objective #1]

  • Epidemiology
  • Defining clinical features
  • Risk factors
  • Statistics
  • Guidance on screening criteria in oncology patients at high risk of bone fracture
  • Patient cases

Treatment options [Learning objectives #2, 3, 4, & 5]

  • Goal of treatments
    • A review of present pharmacotherapy; the roles of:
    • RANKL inhibitors
    • Bisphosphonates
    • Barriers to optimal care in oncology patients at high risk of bone fracture

Summary, conclusions, and best practice recap


Target Audience:

The following healthcare professionals: oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.

Program Objectives:

By the end of the session the participant will be able to:

    • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
    • Describe the criteria for initiation of pharmacotherapy in a patient receiving aromatase inhibitor (AI) therapy or androgen deprivation therapy and apply them to a patient case
    • Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
    • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case


    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.


    Credit Designation: ScientiaCME designates this educational activity for a maximum of  0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


    ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.




    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.75 hours (0.075 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-17-044-H01-P.  ACPE Accreditation effective 11/17/17, expires 11/17/19. 

    This is a Knowledge (K)-type activity.

    Release Date: November 17, 2017
    Expiration Date: November 17, 2019

    Faculty: Azeez Farooki MD

    Faculty Disclosure and Resolution of COI:

    As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


    Faculty Disclosure:  Dr. Azeez Farooki, MD, Associate Clinical Member Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York  has worked as a consultant for Amgen.


    Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.


    Commercial Support Disclosure: This program is supported by educational grants from AMGEN.

    Additional Courses That Are Related To This Course

    Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

    Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options

    Male Osteoporosis Management: Advances in Pharmacotherapy

    Osteoporosis Management: Advances in Pharmacotherapy


    Viewing Instructions



    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

This program is supported by educational grants from AMGEN.


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.